Antiviral therapy in patients with HCV-cirrhosis

Annals of Hepatology

Volumn 8, Issue 4, 2009, Pages 292-297

  Melero, Josep ^a   Berenguer, Marina ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Hepatitis c virus; Liver cancer; Liver cirrhosis; Liver transplantation

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; ALPHA2A INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; CLINICAL ASSESSMENT; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; INFECTION RISK; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FUNCTION; LOW DRUG DOSE; PORTAL VEIN BLOOD PRESSURE; SCORING SYSTEM; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; HEPATITIS C VIRUS; PATHOPHYSIOLOGY; REVIEW; VIROLOGY;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 77953287162     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31741-7     Document Type: Article

References (35)

1. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27(1): 201-205.
2. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32(4): 673-684.
3. Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat 2000; 7(2): 87-92.
4. Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28(5): 756-763.
5. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28(3): 823-830.
6. Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39(3): 389-396.
7. Iacobellis A, Ippolito A, Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008; 14(42): 6467-6472.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-982.
9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965.
10. Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo G, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47(4): 484-491.
11. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. He-patology 2005; 42(2): 255-262.
12. lacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46(2): 206-212.
13. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cava-liere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9(9): 905-915.
14. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8(4): 350-355.
15. Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, Perez del Pulgar, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009; 50(4): 719-728.
16. lacobellis A, Siciliano M, Annicchiarico BE, Valvano MR, Niro GA, et al. Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009; 30(2): 146-153.
17. Wiesner RH, Sorrell M, Villamil F; International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9(11): S1-S9.
18. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV, et al. For the National Institutes of Health Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8(5): 433-439.
19. Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99(1): 57-63.
20. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. Lamivudine North American Transplant Group.A multi-center United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33(2): 424-432.
21. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely de-compensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34(2): 411-416.
22. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123(2): 483-491.
23. Afdhal N, Freilish B, Levine R, et al. Colchicine versus Peg-Intron long term (COPILOT) trial: Interim analisis of clinical outcomes at year 2. Hepatology 2004; 40: 239A.
24. Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004; 35(1): 107-112.
25. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122(5): 1303-1313.
26. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132(7): 517-24.
27. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83(5): 901-909.
28. Rincon D, Ripoll C, Lo lacono O, Salcedo M, Catalina MV, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006; 101(10): 2269-2274.
29. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, et al. Rapid suppression of hemato-poiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123(1): 141-151.
30. Almasio PL, Venezia G, Craxi A. The impact of antiviral therapy on the course of chronic HCV infection. A systematic review. Panminerva Med 2003; 45(3): 175-182.
31. Manfredi R, Sabbatani S. Multiple, repeated filgrastim treatment cycles to recover severe, recurring pegylated interferon-related neutropenia. Hepatogastroenterology 2007; 54(78):
32. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38(3): 645-652.
33. Spivak JL. The blood in systemic disorders. Lancet 2000; 355(9216): 1707-1712.
34. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, et al. Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126(5): 1302-1311.
35. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, et al. TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357(22): 2227-2236.